Volume 7, Issue 1 (3-2021)                   RABMS 2021, 7(1): 1-10 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Bordbar-Bonab S, Mahbob S, Vahed-Jabari M, Dolatkhah H. The effect of Sclareol on the expression of MDR-1 gene and Glycoprotein-P Level in MKN-45 human gastric cancer cells. RABMS. 2021; 7 (1) :1-10
URL: http://ijrabms.umsu.ac.ir/article-1-147-en.html
MSc Student in Biochemistry, Dept. of Biological Sciences, Tabriz Higher Education Institute of Rab-Rashid, Tabriz, Iran , bordbarsaba@gmail.com
Abstract:   (1046 Views)
Background & Aims:  In recent years, the emergence of multidrug resistance in gastric cancer has been a major challenge in treatment of gastric cancer. To deal with the problem, studies and researches were conducted on Sclareol and have turned up the anti-cancer effect of the compound and have also determined the molecular mechanism of it to some extent. Therefore, the main purpose of this study was to investigate the effect of the substance extracted from Salvia Officinalis called Sclareol on MDR-1 gene expression and consequently on the rate of P-glycoprotein in human gastric cancer cell line MKN-45.
Materials and Methods: Cell line MKN-45 was purchased from the Pasteur Institute of Iran and cultured in complete RPMI 1640 Medium with Fetal Bovine Serum, with 20, 40, 60, 80 and 100 μM concentrations of Sclareol treatment for 5 hours. The rate of expression of MDR-1 gene was assessed by Real Time-PCR method and that of P-GP was assessed by Western blotting method.
Results: The expression of MDR-1 gene was significantly reduced at doses of 20, 40 and 60 μmol of Sclareol, while at doses of 80 and 100 μmol there was not seen much effect (p <0.0001). Also, P-glycoprotein showed a very high decrease at doses of 40 and 60 μmol of Sclareol, but no decrease was seen at doses of 80 and 100 μmol (p <0.0001).
Conclusion: From the results of this study, it seems that doses between 20 and 60 μmol of Sclareol can be useful in reducing drug resistance, but doses above 60 mmol do not have such an effect.
Full-Text [PDF 738 kb]   (629 Downloads)    
Type of Study: orginal article | Subject: Special

References
1. Ruan T, Liu W, Tao K, Wu C. A Review of Research Progress in Multidrug-Resistance Mechanisms in Gastric Cancer. Onco Targets Ther 2020;13:1797-807. [DOI:10.2147/OTT.S239336] [PMID] [PMCID]
2. Geretto M, Pulliero A, Rosano C, Zhabayeva D, Bersimbaev R, Izzotti A. Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators. Am J Cancer Res 2017;7(6):1350-71. [pubmed]
3. Bukowski K, Kciuk M, Kontek R. Mechanisms of Multidrug Resistance in Cancer Chemotherapy. Int J Mol Sci 2020 May 2;21(9). [DOI:10.3390/ijms21093233] [PMID] [PMCID]
4. Park J-E, Lee K-E, Jung E, Kang S, Kim YJ. Sclareol isolated from Salvia officinalis improves facial wrinkles via an antiphotoaging mechanism. J Cosmet Dermatol. 2016 Dec;15(4):475-83. [DOI:10.1111/jocd.12239] [PMID]
5. Sitarek P, Merecz-Sadowska A, Śliwiński T, Zajdel R, Kowalczyk T. An In Vitro Evaluation of the Molecular Mechanisms of Action of Medical Plants from the Lamiaceae Family as Effective Sources of Active Compounds against Human Cancer Cell Lines. Cancers (Basel). 2020 Oct 13;12(10). [DOI:10.3390/cancers12102957] [PMID] [PMCID]
6. Li W, Ping Z, Xuemei G, Minglian L, Hongjuan M, Yi H, et al. Naturally Occurring Sclareol Diterpene Augments the Chemosensitivity of Human Hela Cervical Cancer Cells by Inducing Mitochondrial Mediated Programmed Cell Death, S-Phase Cell Cycle Arrest and Targeting Mitogen-Activated Protein Kinase (MAPK) / Extracellular-Signal-Regulated Kinase (ERK) Signaling Pathway. Med Sci Monit 2020;26:e920248. [DOI:10.12659/MSM.920248]
7. Afshari H, Nourbakhsh M, Salehi N, Mahboubi-Rabbani M, Zarghi A, Noori S. STAT3-mediated Apoptotic-enhancing Function of Sclareol Against Breast Cancer Cells and Cell Sensitization to Cyclophosphamide. Iran J Pharm Res 2020;19(1):398-412. [PMCID]
8. Dai Z, Wang Z. Photoactivatable Platinum-Based Anticancer Drugs: Mode of Photoactivation and Mechanism of Action. Molecules 2020 Nov 6;25(21). [DOI:10.3390/molecules25215167] [PMID] [PMCID]
9. Duan M, Ulibarri J, Liu KJ, Mao P. Role of Nucleotide Excision Repair in Cisplatin Resistance. Int J Mol Sci 2020;21(23). [DOI:10.3390/ijms21239248] [PMID] [PMCID]
10. Zhang D, Kanakkanthara A. Beyond the Paclitaxel and Vinca Alkaloids: Next Generation of Plant-Derived Microtubule-Targeting Agents with Potential Anticancer Activity. Cancers (Basel) 2020 Jun 29;12(7). [DOI:10.3390/cancers12071721] [PMID] [PMCID]
11. Robinson K, Tiriveedhi V. Perplexing Role of P-Glycoprotein in Tumor Microenvironment. Front Oncol 2020;10:265. [DOI:10.3389/fonc.2020.00265] [PMID] [PMCID]
12. Callaghan R, Luk F, Bebawy M. Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy? Drug Metab Dispos 2014 Apr;42(4):623-31. [DOI:10.1124/dmd.113.056176] [PMID] [PMCID]
13. Hassan ZM, Yaraee R, Zare N, Ghazanfari T, Sarraf Nejad AH, Nazori B. Immunomodulatory affect of R10 fraction of garlic extract on natural killer activity. Int Immunopharmacol 2003 Oct;3(10-11):1483-9. [DOI:10.1016/S1567-5769(03)00161-9]
14. Noori S, Hassan ZM, Mohammadi M, Habibi Z, Sohrabi N, Bayanolhagh S. Sclareol modulates the Treg intra-tumoral infiltrated cell and inhibits tumor growth in vivo. Cell Immunol. 2010;263(2):148-53. [DOI:10.1016/j.cellimm.2010.02.009] [PMID]
15. Waghray D, Zhang Q. Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment. J Med Chem 2018;61(12):5108-21. [DOI:10.1021/acs.jmedchem.7b01457] [PMID] [PMCID]
16. Robey RW, Shukla S, Finley EM, Oldham RK, Barnett D, Ambudkar SV, et al. Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)). Biochem Pharmacol 2008; 75(6):1302-12. [DOI:10.1016/j.bcp.2007.12.001] [PMID] [PMCID]
17. Zhao L, Pan Y, Gang Y, Wang H, Jin H, Tie J, et al. Identification of GAS1 as an epirubicin resistance-related gene in human gastric cancer cells with a partially randomized small interfering RNA library. J Biol Chem 2009;284(39):26273-85. [DOI:10.1074/jbc.M109.028068] [PMID] [PMCID]
18. Gürel S, Yerci O, Filiz G, Dolar E, Yilmazlar T, Nak SG, et al. High expression of multidrug resistance-1 (MDR-1) and its relationship with multiple prognostic factors in gastric carcinomas in patients in Turkey. J Int Med Res 1999;27(2):79-84. [DOI:10.1177/030006059902700204] [PMID]
19. Choi J-H, Lim H-Y, Joo HJ, Kim HS, Yi JW, Kim HC, et al. Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer 2002;86(10):1578-85. [DOI:10.1038/sj.bjc.6600305] [PMID] [PMCID]
20. Yabuki N, Sasano H, Kato K, Ohara S, Toyota T, Nagura H, et al. Immunohistochemical study of DNA topoisomerase II in human gastric disorders. Am J Pathol 1996;149(3):997-1007. [PMID]
21. Dimas K, Hatziantoniou S, Tseleni S, Khan H, Georgopoulos A, Alevizopoulos K, et al. Sclareol induces apoptosis in human HCT116 colon cancer cells in vitro and suppression of HCT116 tumor growth in immunodeficient mice. Apoptosis 2007;12(4):685-94. [DOI:10.1007/s10495-006-0026-8] [PMID]
22. Zhang T, Wang T, Cai P. Sclareol inhibits cell proliferation and sensitizes cells to the antiproliferative effect of bortezomib via upregulating the tumor suppressor caveolin-1 in cervical cancer cells. Mol Med Rep 2017;15(6):3566-74. [PMID]
23. Dimas K, Papadaki M, Tsimplouli C, Hatziantoniou S, Alevizopoulos K, Pantazis P, et al. Labd-14-ene-8,13-diol (sclareol) induces cell cycle arrest and apoptosis in human breast cancer cells and enhances the activity of anticancer drugs. Biomed Pharmacother 2006;60(3):127-33. [DOI:10.1016/j.biopha.2006.01.003] [PMID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Journal of Research in Applied and Basic Medical Sciences

Designed & Developed by : Yektaweb